Viridian Therapeutics to Webcast Presentation at the 41st Annual J.P. Morgan Healthcare Conference
03 Januar 2023 - 2:00PM
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a
biopharmaceutical company focused on discovering and developing
potential best-in-class medicines for serious and rare diseases,
today announced that its President and Chief Executive Officer,
Jonathan Violin, Ph.D., will present an overview of the company
along with its upcoming corporate priorities at the 41st Annual
J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at
2:15 p.m. PST / 5:15 p.m. EST in San Francisco, California.
In addition, the Company will webcast the question-and-answer
breakout session immediately following its presentation at 2:35
p.m. PST / 5:35 p.m. EST.
The live webcast of the presentation and breakout session can be
accessed under “Events and Presentations” on the Investors section
of the Viridian website at viridiantherapeutics.com. A replay of
the webcast will be available on the Company’s website after the
event until February 8, 2023.
About Viridian Therapeutics
Viridian Therapeutics is a biopharmaceutical company focused on
engineering and developing potential best-in-class medicines for
patients with serious and rare diseases. Viridian’s expertise in
antibody discovery and engineering enables it to develop
differentiated therapeutic candidates for previously validated drug
targets in commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the
treatment of patients with thyroid eye disease (TED). The Company
recently initiated its first global Phase 3 trial called ‘THRIVE’
to evaluate the safety and efficacy of VRDN-001 in patients with
active TED. Viridian is also evaluating VRDN-001 in a Phase 2
proof-of-concept trial in patients with chronic TED. In addition to
its intravenously administered VRDN-001 program, the Company is
advancing two candidates for its subcutaneous strategy with the
goal of providing a more conveniently administered therapy to
patients with TED. Viridian is developing multiple preclinical
assets in autoimmune and rare diseases.
Viridian is based in Waltham, Massachusetts. For more
information, please visit www.viridiantherapeutics.com. Follow
Viridian on LinkedIn.
Investor and Media Contact:Todd JamesViridian
Therapeutics, Inc.Senior Vice President, Corporate Affairs and
Investor RelationsIR@viridiantherapeutics.com
Source: Viridian Therapeutics, Inc.
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024